In this difficult times where everybody around the world are learning maybe a new way of life, one issue the pharmaceutical industry is facing in LATAM is that some Health Authorities in the region do not have implemented technical solutions to allow them to continue the regulatory process virtually. In some cases they were not able to develop remote work, just simple suspended the regulatory activities, with the huge impact in the approval of procedures like clinical trials authorizations or the approval of new products, in the following months, impacting directly the patients.